Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $3.16, $2.17 better than the analyst estimate of $0.99. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $474.26 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
- Enhanced Group Inc. (ENHA) Reports Q2 Loss of $0.53
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
